Growth Metrics

Gilead Sciences (GILD) Total Debt Growth (3y) (2012 - 2026)

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr) Total Debt Growth (3y) (Qtr)
1 Novartis Ag 107,124,802.25 Bn 107,124,802.25 Bn - -
2 Eli Lilly 969.00 Bn 963.72 Bn 16.22 Bn 31.94%
3 Johnson & Johnson 539.46 Bn 517.41 Bn 15.96 Bn 1.29%
4 AbbVie 376.92 Bn 367.57 Bn 10.78 Bn 1.29%
5 Merck 285.00 Bn 279.35 Bn 12.09 Bn 16.90%
6 Amgen 177.58 Bn 165.55 Bn 5.87 Bn -2.37%
7 Gilead Sciences 163.22 Bn 155.50 Bn 5.52 Bn -4.22%
8 Pfizer 145.86 Bn 133.09 Bn -1.21 Bn 21.55%
9 Bristol Myers Squibb 111.90 Bn 101.44 Bn 8.07 Bn 5.53%
10 Gsk 88.34 Bn 83.66 Bn - 3.11%

Historic Data

Download Data 🔒
DateValue
Mar 31, 2026 -4.22%
Dec 31, 2025 -0.39%
Sep 30, 2025 -0.37%
Jun 30, 2025 -1.64%
Mar 31, 2025 -1.62%
Dec 31, 2024 0.02%
Sep 30, 2024 -5.66%
Jun 30, 2024 -8.19%
Mar 31, 2024 -5.83%
Dec 31, 2023 -7.33%
Sep 30, 2023 -5.16%
Jun 30, 2023 1.56%
Mar 31, 2023 1.56%
Dec 31, 2022 0.86%
Sep 30, 2022 0.85%
Jun 30, 2022 0.17%
Mar 31, 2022 -0.47%
Dec 31, 2021 -0.77%
Sep 30, 2021 0.45%
Jun 30, 2021 1.26%
Mar 31, 2021 1.26%
Dec 31, 2020 -2.17%
Sep 30, 2020 0.03%
Jun 30, 2020 -2.86%
Mar 31, 2020 -2.90%
Dec 31, 2019 -2.27%
Sep 30, 2019 -3.16%
Jun 30, 2019 5.64%
Mar 31, 2019 5.21%
Dec 31, 2018 7.40%
Sep 30, 2018 7.12%
Jun 30, 2018 33.28%
Mar 31, 2018 32.95%
Dec 31, 2017 39.32%
Sep 30, 2017 45.96%
Jun 30, 2017 40.38%
Mar 31, 2017 38.99%
Dec 31, 2016 58.34%
Sep 30, 2016 54.69%
Jun 30, 2016 44.47%
Mar 31, 2016 41.84%
Dec 31, 2015 38.93%
Sep 30, 2015 36.33%
Jun 30, 2015 10.49%
Mar 31, 2015 9.45%
Dec 31, 2014 17.70%
Sep 30, 2014 34.20%
Jun 30, 2014 34.82%
Mar 31, 2014 29.61%
Dec 31, 2013 23.95%
Sep 30, 2013 126.14%
Mar 31, 2013 941.07%
Dec 31, 2012 1,037.55%
Sep 30, 2012 249.41%
Jun 30, 2012 182.03%